Delivery of interleukin-10 via injectable hydrogels improves renal outcomes and reduces systemic inflammation following ischemic acute kidney injury in mice

American Journal of Physiology - Renal Physiology

Volumn 311, Issue 2, 2016, Pages F362-F372

  Soranno, Danielle E ^a   Rodell, Christopher B ^b   Altmann, Christopher ^a   Duplantis, Jane ^a   Andres Hernando, Ana ^a   Burdick, Jason A ^b   Faubel, Sarah ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute kidney injury; Chronic kidney disease; Hyaluronic acid; Injectable hydrogels; Interleukin 10

Indexed keywords

COLLAGEN TYPE 3; HYALURONIC ACID; INTERLEUKIN 10; INTERLEUKIN 6; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SODIUM CHLORIDE; HYDROGEL; INTERLEUKIN-6, MOUSE; LCN2 PROTEIN, MOUSE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; FIBROBLAST; HISTOPATHOLOGY; HYDROGEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; KIDNEY CAPSULE; KIDNEY FIBROSIS; KIDNEY FUNCTION; LUNG DISEASE; MALE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; ACUTE KIDNEY INJURY; ANIMAL; C57BL MOUSE; COMPLICATION; FIBROSIS; KIDNEY; KIDNEY FUNCTION TEST; LUNG; METABOLISM; PATHOLOGY; REPERFUSION INJURY;

ACUTE KIDNEY INJURY; ANIMALS; DRUG DELIVERY SYSTEMS; FIBROSIS; HYALURONIC ACID; HYDROGELS; INTERLEUKIN-10; INTERLEUKIN-6; KIDNEY; KIDNEY FUNCTION TESTS; LIPOCALIN-2; LUNG; MALE; MICE; MICE, INBRED C57BL; REPERFUSION INJURY;

EID: 84984666486     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00579.2015     Document Type: Article

References (26)

1. Aguado BA, Mulyasasmita W, Su J, Lampe KJ, Heilshorn SC. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A 18: 806–815, 2012.
2. Ahuja N, Andres-Hernando A, Altmann C, Bhargava R, Bacalja J, Webb RG, He Z, Edelstein CL, Faubel S. Circulating IL-6 mediates lung injury via CXCL1 production after acute kidney injury in mice. Am J Physiol Renal Physiol 303: F864–F872, 2012.
3. Andres-Hernando A, Altmann C, Bhargava R, Okamura K, Bacalja J, Hunter B, Ahuja N, Soranno D, Faubel S. Prolonged acute kidney injury exacerbates lung inflammation at 7 days post-acute kidney injury. Physiol Rep 2: e12084, 1–12, 2014.
4. Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater 23: H41–H56, 2011.
5. Chawla LS. Acute kidney injury leading to chronic kidney disease and long-term outcomes of acute kidney injury: the best opportunity to mitigate acute kidney injury? Contrib Nephrol 174: 182–190, 2011.
6. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 79: 1361–1369, 2011.
7. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371: 58–66, 2014.
8. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 82: 516–524, 2012.
9. Chuang ST, Kuo YH, Su MJ. Antifibrotic effects of KS370G, a caffeamide derivative, in renal ischemia-reperfusion injured mice and renal tubular epithelial cells. Sci Rep 4: 5814, 2014.
10. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60: 2118–2128, 2001.
11. Furuichi K, Kaneko S, Wada T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 13: 9–14, 2009.
12. Gaffey AC, Chen MH, Venkataraman CM, Trubelja A, Rodell CB, Dinh PV, Hung G, MacArthur JW, Soopan RV, Burdick JA, Atluri P. Injectable shear-thinning hydrogels used to deliver endothelial progenitor cells, enhance cell engraftment, and improve ischemic myocardium. J Thorac Cardiovasc Surg 150: 1268–1276, 2015.
13. Gao J, Liu R, Wu J, Liu Z, Li J, Zhou J, Hao T, Wang Y, Du Z, Duan C, Wang C. The use of chitosan based hydrogel for enhancing the therapeutic benefits of adipose-derived MSCs for acute kidney injury. Biomaterials 33: 3673–3681, 2012.
14. Guvendiren M, Lu HD, Burdick JA. Shear-thinning hydrogels for biomedical applications. Soft Matter 8: 260–272, 2012.
15. Hubner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, Freitag-Wolf S, Bewig B. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44: 507–511, 2008.
16. Humphreys BD. Introduction: stem cells and kidney regeneration. Semin Nephrol 34: 349–350, 2014.
17. Humphreys BD. Kidney injury, stem cells and regeneration. Curr Opin Nephrol Hypertens 23: 25–31, 2014.
18. Humphreys BD. Kidney structures differentiated from stem cells. Nat Cell Biol 16: 19–21, 2014.
19. Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med 59: 311–325, 2008.
20. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. Lancet 382: 170–179, 2013.
21. Liu G, Zhao L, Wang T, Zhang M, Pei H. Optimal therapeutic dose and time window of picroside II in cerebral ischemic injury. Neural Regen Res 9: 1437–1445, 2014.
22. Mehta RL, Cerda J, Burdmann EA, Tonelli M, Garcia-Garcia G, Jha V, Susantitaphong P, Rocco M, Vanholder R, Sever MS, Cruz D, Jaber B, Lameire NH, Lombardi R, Lewington A, Feehally J, Finkelstein F, Levin N, Pannu N, Thomas B, Aronoff-Spencer E, Remuzzi G. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 385: 2616–2643, 2015.
23. Rodell CB, MacArthur JW, Dorsey SM, Wade RJ, Wang LL, Woo YJ, Burdick JA. Shear-thinning supramolecular hydrogels with secondary autonomous covalent crosslinking to modulate viscoelastic properties in vivo. Adv Funct Mater 25: 636–644, 2015.
24. Rodell CB, Rai R, Faubel S, Burdick JA, Soranno DE. Local immunotherapy via delivery of interleukin-10 and transforming growth factor beta antagonist for treatment of chronic kidney disease. J Control Release 206: 131–139, 2015.
25. Soranno DE, Lu HD, Weber HM, Rai R, Burdick JA. Immunotherapy with injectable hydrogels to treat obstructive nephropathy. J Biomed Mater Res A 102: 2173–2180, 2014.
26. Wang L, Chen H, Liu XH, Chen ZY, Weng XD, Qiu T, Liu L, Zhu HC. Ozone oxidative preconditioning inhibits renal fibrosis induced by ischemia and reperfusion injury in rats. Exp Ther Med 8: 1764–1768, 2014.